Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Holding GH?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.78Last Year’s EPS
-$1.58Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 25.23%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted a strong quarter with record revenue growth and successful product launches, particularly for Guardant360 and Shield. However, some challenges such as weather impacts on volume and slower progress in Japan were noted. Overall, the company demonstrated strong operational and financial performance with positive forward-looking expectations.Company Guidance
During the Guardant Health Q3 2024 earnings call, the company provided several key metrics and guidance points. Total revenue for the quarter grew by 34% to a record $191.5 million, driven by a 35% increase in precision oncology revenue, with clinical test volume reaching 53,100 tests, reflecting a year-over-year growth of 21%. The company achieved a significant milestone with Guardant360 ASPs reaching $3,000, four years ahead of the target. Guardant Health also reported a positive reception for its Shield blood test for colorectal cancer screening, receiving a Medicare price of $920, with expectations to secure an ADLT designation for an even higher ASP in 2025. For the full year 2024, Guardant Health raised its revenue guidance to a range of $720 million to $725 million, representing growth of 28% to 29% compared to 2023. The company anticipates accelerating clinical volume growth above 20% in 2025, driven by the traction of Guardant360, Reveal, and TissueNext, alongside expected reimbursements and cost reductions.Record Revenue Growth
Total revenue grew 34% to a record $191.5 million, driven by precision oncology revenue which increased 35%.
Strong Growth in Clinical Test Volume
Clinical test volume for the third quarter grew 21% year-over-year and 7% quarter-over-quarter, reaching 53,100 tests.
Biopharma Segment Success
Biopharma revenue grew 34% year-over-year with biopharma test volumes up 40%, reaching a record 10,500 tests.
Medicare Pricing and ASP Achievement
Guardant360 ASP reached $3,000 in Q3 2024, ahead of target. Shield received a Medicare price of $920.
Positive Free Cash Flow in Therapy Selection
Generated positive free cash flow in the Therapy Selection business in the third quarter.
Launch of Shield Blood Test
Successful launch of Shield blood test for colorectal cancer screening with strong initial demand.
---
GH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $25.29 | $28.59 | +13.05% |
| Aug 07, 2024 | $33.96 | $30.27 | -10.87% |
| May 09, 2024 | $19.44 | $22.37 | +15.07% |
| Feb 22, 2024 | $22.27 | $19.42 | -12.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Guardant Health (GH) report earnings?
Guardant Health (GH) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Guardant Health (GH) earnings time?
Guardant Health (GH) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GH EPS forecast?
GH EPS forecast for the fiscal quarter 2024 (Q4) is -$0.78.
---